All In Biotech

BLA 761163 · Morphosys US INC

Monjuvi

Tafasitamab-Cxix · Intravenous

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 31, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

58

6 Phase 3, 21 recruiting

FAERS reports

906

665 serious, 131 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 2, 2026.

MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )

Mechanism: Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). In studies conducted in vitro in DLBCL tumor cells, tafasitamab-cxix in combination with lenalidomide resulted in increased ADCC activity compared to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 18, 2025 Supplement 13 · Efficacy · priority review OrphanLabelLetter
  • Jul 31, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • MONJUVI · TAFASITAMAB-CXIX 12MG/KG · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tafasitamab" as an intervention, any sponsor and status, largest first.

All 58 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression239
  • off label use168
  • lymphoma165
  • death66
  • drug ineffective47
  • diffuse large b-cell lymphoma42
  • neutropenia39
  • blood lactate dehydrogenase increased38
  • malignant neoplasm progression38
  • covid-1930
  • polyneuropathy29
  • diarrhoea28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202012
202193
2022179
2023380
2024135
202565
202642

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Monjuvi (Tafasitamab-Cxix)

2024 spending

$1.0M

Beneficiaries

14

75 claims

Per beneficiary

$74,016

$1,323.40 per unit

View as table
YearSpending
2020$0
2021$808,990
2022$312,555
2023$1,179,804
2024$1,036,223

Part B: Monjuvi (Tafasitamab-Cxix) · HCPCS J9349

2024 spending

$43.1M

Beneficiaries

545

5,980 claims

Per beneficiary

$79,155

2024 ASP limit $13.66 per unit

View as table
YearSpending
2020$0
2021$32,609,272
2022$47,897,377
2023$46,746,005
2024$43,139,723

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Morphosys US INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.